Skip to main content
. Author manuscript; available in PMC: 2024 Sep 19.
Published in final edited form as: Circulation. 2023 Aug 25;148(12):936–946. doi: 10.1161/CIRCULATIONAHA.123.064556

Figure 2. Cumulative Incidence for Bleeding Outcomes by Predicted Risk Category in the Validation Cohorts: COMBINE-AF and RAMQ.

Figure 2.

Figure 2.

Presented are the Cumulative Incidence curves for individuals in the COMBINE-AF clinical trial cohort (2A), and RAMQ administrative database (2B). Cumulative incidence curves were based on the risk category assigned to individuals by the DOAC Score. Risk-scores were 0-10, with risk categories assigned as: very low (score 0-3), low (score 4-5), moderate (score 6-7), high (score 8-9) and very high (score 10). Individuals in COMBINE-AF were included if they were on any direct-acting oral anticoagulant (DOAC). Individuals in RAMQ AF were included if they were on apixaban 5mg twice per day or rivaroxaban 20mg daily.

A) Cumulative Incidence for Major Bleeding by Risk Category in COMBINE-AF

B) Cumulative Incidence for Major Bleeding by Risk Category in RAMQ